1. Introduction {#sec1}
===============

Multiple sclerosis (MS) is a chronic demyelinating and inflammatory disorder of the central nervous system (CNS) affecting approximately 2.5 million people worldwide \[[@B1], [@B2]\]. It is characterized by immune-mediated cellular damage in the white and grey matters \[[@B3]\]. The etiology of MS remains unclear although both genetic and environmental factors are involved in disease onset and development \[[@B4], [@B5]\]. The hallmark feature of MS lesion is the destruction of the myelin sheath, followed by formation of demyelinating plaques and loss of axons considered to be a marker of disease progression \[[@B6], [@B7]\].

The disease is related to a T cell-dependent process which is associated with macrophage-mediated demyelination due to myelin-specific autoantigens. Additionally, many critical players are involved in the pathogenesis of MS, including different immune cells, such as T helper lymphocytes (Th1 and Th17), B cells, or several autoantibodies directed against CNS components \[[@B8]\]. Meanwhile, infiltration of lymphocytes and monocytes from the peripheral blood into the brain is observed in acute active MS lesions \[[@B9]\]. According to some studies, immune-mediated myelin loss and mitochondrial dysfunction seem to play a crucial role in MS \[[@B10], [@B11]\]. Different factors including oxidative stress cause mitochondrial destruction \[[@B12]--[@B14]\]. As a result, mitochondria are the main source of reactive oxygen species (ROS) and reactive nitrogen species (RNS) \[[@B15], [@B16]\]. In the case of mitochondrial dysfunction, overproduction of toxic reactive species is observed. It plays a pivotal function in myelin and oligodendrocyte loss. They are many various types of RNS involved in the pathophysiology of MS, most of which are unstable due to their short lifetime. Additionally, most RNS are difficult to detect due to coexistence of many antioxidants in vivo. The role of nitric oxide (NO) and its reactive derivative (peroxynitrite) is well documented in the pathogenesis of MS \[[@B17], [@B18]\]. Nitric oxide is unstable and is rapidly converted to nitrates and nitrites which reflect NO concentrations \[[@B19]\]. In MS the engagement of NO is related to the presence of peroxynitrite activities, NO metabolites, and inducible NO synthase (iNOS) \[[@B20]\]. Moreover, recent studies report dramatically increased oxidative stress in MS patients \[[@B5], [@B21]--[@B23]\], including the occurrence of oxidative protein modifications \[[@B24], [@B25]\]. Furthermore, reduction in antioxidant defense mechanism is involved in the pathogenesis of MS \[[@B26], [@B27]\].

It is well known that MS is an inflammatory disease while NO~*x*~ seems to be important in coordinating inflammatory response. In the course of MS, activated T cells and macrophages secrete proinflammatory cytokines such as interleukins (IL-1 and IL-12), interferon gamma (IFN-*γ*), or tumor necrosis factor alpha (TNF-*α*) \[[@B28]\]. These cytokines can enhance NO formation in the CNS by iNOS \[[@B29]\]. Recent studies have suggested that ROS and RNS lead to oxidative and nitrosative stress responsible for neurodegeneration. However, the association between neuroinflammation, nitrosative, and oxidative stress in MS is still poorly understood. It is still not fully understood which process initiates MS, the disease course or nitrosative and oxidative stress which occurs as a consequence of an inflammatory cascade \[[@B30]\]. Over the past few years many new therapeutic options have been involved in the treatment of MS. The current range of disease-modifying therapy (DMT) includes intervention in antigen presentation and peripheral immune response and in the blood-brain barrier \[[@B31]\]. The first-line agents of DMT \[interferons beta (INF-*β*1a; *β*-1b) and glatiramer acetate (GA)\] decrease proinflammatory cytokines and prevent the migration of activated T cells across the blood-brain barrier \[[@B32]\]. Natalizumab (NT), the second-line agent of DMT, prevents such migration \[[@B33]\] while fingolimod (FG) prevents the emergence of lymphocytes from the lymphoid tissue decreasing lymphocyte infiltration into the CNS \[[@B34]\]. Additionally, FG acts directly on oligodendrocytes, microglia, astrocytes, and neurons \[[@B35]\]. It should be borne in mind that shift from inflammation to neurodegeneration is a significant feature of MS. Both immediate intervention to control inflammation and a delay in the progression of disability are required \[[@B36]\].

The aim of the study was to assess serum nitric oxide as one of the nitrogen species and inflammatory parameters in relapsing-remitting MS (RRMS) and to compare the effectiveness of various types of therapy (first- and second-line agents of DMT) to reduce nitric oxide and inflammatory biomarkers. What is more, we also presented a correlative analysis between serum nitric oxide level and clinical and radiological activity in MS patients. Finally, our aim was also to determine the correlation between nitric oxide concentration and inflammatory parameters in MS patients and healthy controls in the context of the impaired autoimmune system in RRMS subjects.

2. Material and Methods {#sec2}
=======================

2.1. MS Patients and Healthy Controls {#sec2.1}
-------------------------------------

Sixty-three MS patients and 10 healthy subjects were enrolled in a case-control prospective study. All of the study participants were recruited from the Department of Neurology in Zabrze, Medical University of Silesia, Poland. For the present study we chose a group of patients followed up between January and March 2015. All patients had been diagnosed with RRMS, according to the McDonald criteria (2010), and were divided into six study groups:RRMS INF-*β*1a group: 22 patients who received interferon *β*1a (Avonex) applied once per week at the dose of 30 *µ*g as an intramuscular injection.RRMS INF-*β*1b group: 17 patients treated with subcutaneous injections of interferon *β*1b (Extavia or Betaferon) every other day at the dose of 250 *µ*g.RRMS-GA group: 5 patients treated with glatiramer acetate (Copaxone) 20 mg subcutaneously daily.RRMS-NT group: 7 patients who were given NT (Tysabri) intravenously at the dose of 300 mg once per month.RRMS-FG group: 12 patients were treated with 0.5 mg FG (Gilenya)*p.o.*daily.CG (control group): 10 healthy controls age- and sex-matched with the patient group. Healthy controls were diagnosed with insignificant paresthesia in the Department of Neurology and were the residents of the Upper Silesia region and presented lifestyle similar to the study population with MS. None of the patients was treated due to any chronic disease nor did the subjects take any medication permanently.

To reach the goals of our study we divided the subjects into the following two groups: LI group: 44 patients who received the first-line DMT (INF-*β*1a, INF-*β*1b, or GA); LII group: 19 patients treated with the second-line DMT (NT or FG).

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

The inclusion criteria were as follows: age 18--55 years, RRMS according to the McDonald criteria (2010), DMT at least 6 months, and signed written informed consent. The exclusion criteria were as follows: different clinical forms of MS other than RRMS, that is, primary progressive, secondary progressive, relapsing-progressive or clinically isolated syndrome, immunosuppressant treatment, active or symptomatic infection or diagnosis of any disease and/or intake of medication which affect inflammatory process, intake of dietary supplements, vitamins, or antioxidative substances 6 months prior to the study and lack of signed informed consent.

2.3. Study Protocol {#sec2.3}
-------------------

The diagnosis of MS was based on neurological examination, disease history, and magnetic resonance imaging (MRI) findings using the McDonald criteria (2010). The severity of the clinical course in MS patients ranged from 1.0 to 4.5 and was estimated by the Expanded Disability Status Scale (EDSS).

2.4. MRI Examination {#sec2.4}
--------------------

MRI was performed using the 1.5T scanner imaging (General Electric HDx USA) and the standard head protocol for MS patients \[multiple planes, slice thickness of 5 mm, contrast media: Gd (Gadovist), and additional postcontrast 3DT2 sequences (1 mm slice thickness) head MRI\]. MRI examination was carried out in all MS patients in compliance with the standard clinical protocol.

2.5. Laboratory Assays {#sec2.5}
----------------------

Biochemical assays were measured from fasting serum samples taken in the morning. Blood samples were collected between 7.00 and 8.00 and examined microscopically. To eliminate insoluble substances, the samples were centrifuged 30 minutes after collection, frozen, and stored until laboratory measurements.

### 2.5.1. Serum IL-1*β*/IL-1F2 Concentration {#sec2.5.1}

Serum IL-1*β*/IL-1F2 concentration was determined according to the Quantikine Human IL-1*β* immunoassay designed to measure IL-1*β* in cell culture supernates, serum, and plasma. Solid Phase Sandwich enzyme-linked immunosorbent assay (ELISA) with an assay range of 3.9--250 pg/mL was used in the present study.

### 2.5.2. NO Assay {#sec2.5.2}

The measurement of NO was performed to estimate NO metabolites known as nitrite and nitrate (NO~*x*~), whose concentration was used as a marker of NO production and iNOS activity. NO~*x*~ level was expressed as *µ*M. After chemical reduction of nitrate to nitrite using the Griess reaction, we employed the method of Navaro-Gonzalvez et al.

### 2.5.3. Serum C-Reactive Protein Level {#sec2.5.3}

C-reactive protein (CRP), an acute phase protein, was measured with the use of the dry chemistry immunological method and a VITROS 250 analyzer (Ortho Clinical Diagnostics, Johnson and Johnson, USA). Based on the hospital laboratory reference range, CRP concentration above 5 mg/L was considered abnormal.

2.6. Statistical Analysis {#sec2.6}
-------------------------

The continuous variables were presented as the means and standard deviations. The categorical variables were shown as percentages. The groups were compared using the nonparametric Mann--Whitney *U* or the Kruskall-Wallis test for continuous variables and the chi-square test for categorical data. Yates\' correction was applied when appropriate. The relationships between variables were tested using the Spearman rank correlation analysis. Statistical significance was defined as *p* \< 0.05. All statistical analyses were performed using Statistica 12 (Statsoft, Tulsa, Oklahoma, USA).

3. Results {#sec3}
==========

Demographic and clinical characteristics of the studied subjects were summarized in [Table 1](#tab1){ref-type="table"}. All patients and the CG were age- and sex-matched (*p* \> 0.05). No statistically significant differences were observed between 5 RRMS groups, depending on the type of DMT (INF-*β*1a, INF-*β*1b, GA, NT, and FG) with respect to age, age at the beginning of DMT, sex, MS duration, time of DMT, EDSS, T2 and Gd+ (Gadolinium-enhancing) lesions in MRI at the time of diagnosis, new T2 lesions, and new T1 lesions observed within the previous year prior to the enrollment in the study (*p* \> 0.05).

The results of the demographic and clinical characteristics of LI and LII groups were presented in [Table 2](#tab2){ref-type="table"}. We demonstrated a longer duration of MS in LII as compared to the LI group (*p* = 0.048). Patients belonging to the LI group had a longer treatment duration of MS as compared to the LII group (*p* = 0.005). No differences in the other above-mentioned parameters were noted. Serum IL-1*β*/IL-1F2 concentration was similar in healthy controls, RRMS IFN-*β*1a, RRMS IFN-*β*1b, RRMS-GA, RRMS-NT, and RRMS-FG groups (1.64 ± 0.47, 1.43 ± 0.34, 1.56 ± 0.60, 1.71 ± 0.41, 2.19 ± 1.27, and 1.51 ± 0.56 pg/mL, *p* = 0.68, resp.) as well as in the DMT groups without CG evaluation ([Table 3](#tab3){ref-type="table"}). No differences were found in the serum level of IL-1*β*/IL-1F2 between LI and LII groups and healthy controls (1.51 ± 0.46, 1.76 ± 0.92, and 1.64 ± 0.47 pg/mL, *p* = 0.47, resp.) as well as between LI and LII without CG assessment ([Table 4](#tab4){ref-type="table"}). However, in LI serum concentration of NO~*x*~ was significantly higher compared LII ([Table 4](#tab4){ref-type="table"}). The same results were noted in the analysis between LI, LII, and CG (2.04 ± 0.70, 1.57 ± 0.31, and 1.50 ± 0.16 *µ*M, *p* = 0.009, resp.). There were also differences in the level of NO~*x*~ in healthy controls, RRMS IFN-*β*1a, RRMS IFN-*β*1b, RRMS-GA, RRMS-NT, and RRMS-FG groups (1.50 ± 0.16, 2.25 ± 0.71, 1.90 ± 0.69, 1.58 ± 0.35, 1.65 ± 0.31, and 1.52 ± 0.31 *µ*M, *p* = 0.003, resp.) as well as in the DMT groups without CG evaluation ([Table 3](#tab3){ref-type="table"}). Serum CRP level was similar in the CG, INF-*β*1a, INF-*β*1b, GA, NT, and FG groups (1.19 ± 0.55, 2.43 ± 3.14, 1.88 ± 1.71, 1.72 ± 1.12, 0.95 ± 0.79, and 1.81 ± 2.5 mg/L, *p* = 0.78, resp.) and in the DMT groups without CG evaluation ([Table 3](#tab3){ref-type="table"}). No differences in CRP concentration between LI, LII, and the CG were observed (2.13 ± 2.47, 1.49 ± 2.05, and 1.19 ± 0.55, *p* = 0.52, resp.). However, excluding the CG, a comparison between LI and LII revealed a trend to a higher CRP level in LI ([Table 4](#tab4){ref-type="table"}). Considering the EDSS, we estimated serum concentration of NO~*x*~, IL-1*β*/IL-1F2, and CRP in two groups, depending on the EDSS results (0--3 and \>3). No significant differences were found in this analysis ([Table 5](#tab5){ref-type="table"}). Furthermore, we did not observe the correlation between NO~*x*~ and the EDSS, annual relapse rate, and the number of MRI lesions measured in the whole MS population, in LI and LII groups ([Table 6](#tab6){ref-type="table"}). However, a significant correlation between serum NO~*x*~ level and MS duration was observed, which was confirmed in the whole study population (*R* = −0.3046, *p* \< 0.05) ([Figure 1](#fig1){ref-type="fig"}) and in the LI group (*R* = −0.36, *p* \< 0.05) ([Figure 2(a)](#fig2){ref-type="fig"}), unlike in the LII group (*R* = 0.24, *p* \> 0.05) ([Figure 2(b)](#fig2){ref-type="fig"}). We also found a higher serum level of NO~*x*~ when the duration of RRMS was shorter than the median time (\<59.5 months) as compared to the disease duration of \>59.5 months (2.11 ± 0.73 and 1.67 ± 0.45, *p* = 0.01, resp.). Measurements of IL-1*β*/IL-1F2 did not show differences in the groups formed, depending on MS duration (1.53 ± 0.61 versus 1.63 ± 0.67, *p* = 0.65 for \<59.5 months and \>59.5 months, resp.). Furthermore, there were no differences in CRP concentration estimated in the groups formed, depending on MS duration (2.14 ± 2.91 versus 1.75 ± 1.67, *p* = 0.73 for \<59.5 months and \>59.5 months, resp.). Interestingly, we showed a correlation between serum CRP and IL-1*β*/IL-1F2 concentration in healthy controls (*r* = 0.65091, *p* \< 0.05), whereas no correlations were found in the whole MS population (*R* = −0.1102, *p* \> 0.05) ([Figure 3](#fig3){ref-type="fig"}) in LI ([Figure 4(a)](#fig4){ref-type="fig"}) and in LII ([Figure 4(b)](#fig4){ref-type="fig"}).

4. Discussion {#sec4}
=============

The results of our study demonstrate that MS patients treated with IFN-*β*1a- IFN-*β*1b had significantly higher serum NO~*x*~ levels as compared to the healthy controls. Similarly, previous reports discussed the measurement of NO~*x*~ levels \[[@B19], [@B37]\]. Furthermore, other studies failed to observe a higher NO~*x*~ concentration in the serum of MS patients as compared to healthy controls \[[@B18], [@B21], [@B38]\]. Different outcomes were probably related to the various neurological and clinical status of MS patients, another form of the disease, different lifestyle, diet, or pharmacological interactions.

However, NO~*x*~ is considered a major factor in the pathophysiology of MS \[[@B21]\]. It is produced as a result of a catalytic conversion of L-arginine to citrulline by endothelial and neuronal iNOS. Concomitantly, arginase involved in L-arginine conversion leads to the production of ornithine, favoring cellular regeneration \[[@B39]\]. Additionally, NO~*x*~ creates a family of toxic molecules known as RNS. Finally, it leads to nitrosylation resulting in cellular death \[[@B3]\]. High levels of NO~*x*~ are implicated in active MS lesions produced by astrocytes and microglia, as an after-effect of the expression of iNOS. It is believed that NO~*x*~ causes tissue damage and blocks axonal conduction and results in degeneration \[[@B17]\]. On the other hand, under normal conditions NO is known to be a signaling molecule regulating cellular functions, neurotransmission, vasodilatation, and immune response, mediated by cyclic guanosine monophosphate. In contrast, toxic properties of NO~*x*~ are related to the above-mentioned RNS. Therefore, it is suggested that NO plays a conflicting role in the pathophysiology of neuroimmunological diseases such as MS with pro-and anti-inflammatory activities, depending on local concentrations. Under physiological conditions high concentration of NO is considered to be a neuroprotective factor \[[@B39]\]. However, MS is a chronic inflammatory disorder with impaired immune regulation, resulting in a high activity of serum NO~*x*~ in MS patients. It has recently been reported that persistent inflammatory response results in greater iNOS expression and NO production, while arginase activity predominates under physiological conditions with increased Th2 cytokine expression \[[@B40]\]. It seems that the data from our study are consistent with these findings.

Despite the involvement of various inflammatory mediators in immunity, only a few cytokines seem to be essential for the development of CNS autoimmunity. Recently IL-1 has been recognized as a pivotal factor in experimental autoimmune encephalomyelitis and MS, initiating and expanding the disease \[[@B41]\]. There is a growing evidence for the impact of IL-1 on neuroinflammation \[[@B42]\]. Additionally, IL-1 induced Bhlhe40 expression in polarized Th17 cells in a model of autoimmune neuroinflammation \[[@B43]\]. Based on the above findings, IL-1*β*/IL-1F2 is a proinflammatory cytokine which we initially considered a potential factor activating inflammatory process in MS patients.

In the CNS of MS patients continued inflammatory process with impaired immune regulation is observed. This phenomenon results in high activity of serum NO~*x*~. Concomitantly, it has recently been reported that persistent inflammatory response results in greater iNOS expression \[[@B40]\]. Reports confirm the damage to the inflamed nerve tissue which is due to NO~*x*~. Impaired blood-brain barrier is the result of vasodilatation, which promotes the passage of inflammatory cells to the CNS \[[@B44], [@B45]\]. Consequently, increased permeability of the blood-brain barrier at the sites of inflammatory lesions is observed \[[@B46]\]. On the other hand, it is well documented that DMTs (INF-*β*1a, INF-*β*1b, and GA) slow the progressive nerve damage thus changing the course of the disease. This mechanism is still poorly understood. However, DMTs are suspected to downregulate inflammatory cytokines and reduce blood-brain barrier permeability and T-cell migration into the CNS. The second-line agents (e.g., NT monoclonal antibody) decrease inflammatory response by blocking receptors on white blood cells which allow them to enter the brain and the spinal cord \[[@B3]\]. Fingolimod is able to interfere with the inflammatory phase of MS through the prevention of lymphocyte infiltration into the CNS \[[@B34]\]. Additionally, FG affects positively damaged myelin regions binding to S1P receptor on oligodendrocytes \[[@B47]\].

In our study we assumed that higher NO~*x*~ level is linked to the presence of greater inflammation and nitrosative stress in the serum of MS patients. Therefore, anti-inflammatory effect of DMT resulted in decreased NO~*x*~ serum concentration. Considering higher NO~*x*~ serum activity obtained from patients treated with the first-line DMT (IFN-*β*1a; IFN-*β*1b) as compared to the second-line, we could hypothesize that the second-line agents produce a better anti-inflammatory and antinitrosative effect. Additionally, these agents decrease the extent of nerve damage due to NO~*x*~ in the inflammatory process. Moreover, based on the analysis of patients under second-line DMT who previously were given the first-line agents, we observed a cumulative anti-inflammatory effect of the first- and second-line DMT in the LII group (serum NO~*x*~ was higher compared to the LI group despite the fact that the time of DMT was shorter in LII). On the other hand, there is evidence that MS patients treated with INF-*β*1b had significantly lower concentrations of NO metabolites in the serum as compared to the untreated MS patients \[[@B48]\]. Additionally, a three-year INF-*β*1a or INF-*β*1b monotherapy is reported to have reduced serum NO~*x*~ levels by 77% and 71%, respectively \[[@B49]\].

Interestingly, we also confirmed that a longer MS duration was correlated with a lower NO~*x*~ serum level. At the same time NO~*x*~ serum concentration was lower when disease duration was above 59.5 months. It suggests that patients of longer disease duration used more DMT starting from the time of diagnosis in comparison with the subjects of shorter disease duration. On the other hand, decreased NO~*x*~ serum activity in patients with disease duration above 59.5 months seems to be justified due to DMT, which limited inflammatory response. However, Ljubisavljevic et al. showed higher serum NO levels of clinical isolated syndrome as compared to the RRMS group, indicating a possible modulation of inflammation during the course of the disease \[[@B39]\]. Nonetheless, RRMS patients had not received interferon within 6 months prior to the study enrollment.

The data from our study showed no correlation between serum NO~*x*~ level and the EDSS in MS patients. However, Rejdak et al. reported a correlation between NO metabolites and the EDSS \[[@B50]\]. Similar data showed a positive correlation between NO~*x*~ and the EDSS in RRMS patients \[[@B51]\]. Contrary to our study, Rejdak et al. assayed the concentration of NO~*x*~ in the cerebrospinal fluid. We did not confirm the correlation between NO~*x*~ serum level and new MRI lesions or lesions detected at the time of diagnosis. However, other authors observed that the concentration of NO~*x*~ in the cerebrospinal fluid correlated with the volume of Gd+ lesions on MRI \[[@B52]\]. It probably corresponds better with axonal degeneration, the EDSS, and MRI lesions as compared to NO~*x*~ serum activity.

Multiple sclerosis is defined as a chronic inflammation of the CNS, while active inflammation and the breakdown of the blood-brain barrier may be detected in MRI brain lesions in MS patients \[[@B53]--[@B55]\]. Inflammation in MS is a dynamic process presented at all stages of the disease \[[@B56]\] and the course of MS depends on the location within the brain (perivascular, meningeal, and parenchymal) and on the clinical aspects such as age or disease duration \[[@B57]\]. Consequently, the evaluation of inflammation remains difficult. Furthermore, inflammatory biomarkers assayed in our study (IL-1*β*/IL-1F2 and CRP) did not differ in all the groups divided, depending on the types of DMT and in the CG. Previously, Soilu-Hänninen et al. also reported that CRP values in MS patients and in healthy controls were similar \[[@B58]\], whereas the results of another study showed significantly increased levels of CRP in RRMS subjects without DMT and in treated RRMS patients \[[@B24]\]. In our study we indicated a trend (*p* = 0.06) toward a higher CRP concentration in the group treated with the first-line DMT as compared to the patients using second-line agents. As in the case of NO~*x*~ level, we should hypothesize better reduction in inflammation using the second-line DMT. Finally, we proved a positive correlation between CRP and IL-1*β*/IL-1F2 serum concentration as the inflammatory indicators in healthy controls. This correlation was not confirmed in the whole MS population. It seems that this phenomenon was due to the immune dysregulation and subsequent impaired inflammatory response in MS patients. As a result, dendritic cells have an activated phenotype in subjects with MS and migrate across the blood-brain barrier inducing differentiation of T cells into proinflammatory Th1 and Th17 lymphocytes. Moreover, activated macrophages and microglia produce other proinflammatory cytokines and nitric and oxide radicals which being responsible for the failure of the CNS in MS patients \[[@B32]\].

Using antioxidant therapy may be beneficial in addition to DMTs. There are already reports on the antioxidant protection of biological targets against ROS. Hence, it has been suggested that antioxidants may be attractive potential therapeutic agents to prevent neuronal damage caused by ROS \[[@B59]\]. However, there is some evidence indicating complex interactions between exogenous and endogenous antioxidant mechanisms. Under physiological conditions, this balance protects from nitrosative and oxidative stress. On the other hand, it is well known that nuclear factor erythroid-derived 2-like 2 (Nrf2) participates in the antioxidant defense. This molecule is strongly involved in regulation of many different genes linked to the inflammatory processes, stem cell regulation, or regeneration \[[@B60]\]. Activation of Nrf2 was reported to inhibit production and secretion of inflammatory cytokines \[[@B61]\]. What is more, Nrf2 activity depends on the presence of radicals. In experimental autoimmune encephalomyelitis (EAE) low levels of antioxidants (*γ*-glutamylcysteine ligase and glutathione synthetase) were observed, which correlated with a diminished expression of Nrf2 \[[@B62]\]. The exogenous antioxidant treatment could potentially reduce nitrosative and oxidative stress. There are some reports on the increased induction of Nrf2-antioxidant mediated genes after vitamin E supplementation \[[@B63]\]. However, it was also observed that anti-inflammatory and antioxidant activities of tocopherols are independent of Nrf2 in mice \[[@B64]\]. Such different results found in the literature may question beneficial effects and clinical efficacy of exogenous antioxidants \[[@B65]\]. Adding antioxidant therapy to the DMTs (with their anti-inflammatory properties) should be well thought out and balanced. Certainly, it requires further investigation in clinical trials.

5. Limitation of the Study {#sec5}
==========================

Although the present study has yielded some preliminary findings, its design is not without flaws. We had to interpret the results very carefully due to the small sample size. We included a relatively small group of MS patients divided into much smaller subgroups depending on DMTs. Despite demonstrating the correlation between NO~*x*~ levels and MS duration for the whole MS study population and LI, such a correlation for LII could not be confirmed. We suppose that this result was due to the LII group which included significantly fewer patients compared to the LI group (19 subjects versus 44, resp.). Hence, to finally confirm NO~*x*~ serum level as a biomarker of MS duration further investigation is required. However, the small sample size was related to the restrictive inclusion criteria used to carefully select MS patients. Therefore, we are planning to include more participants (patients as well as healthy controls) in the future. Relapsing-remitting MS patients will be divided (as previously) into 5 groups, each including 50, 50, 45, 40, and 40 patients who will receive INF-*β*1a, INF-*β*1b, glatiramer acetate, natalizumab, and fingolimod, respectively. Although we described altered serum NO~*x*~ level expression in MS patients it would be beneficial to evaluate some other nitrosative stress biomarkers. Certainly, we would like to measure other biomarkers of RNS production, such as 4,5-diaminofluorescein (DAF-2), 2,3-diaminonaphthalene (DAN), 2,3-naphthotriazole (NAT), nitrosothiols, or nitric oxide synthase (NOS) in the serum of MS patients. Consequently, more biomarkers may reflect the RNS production more effectively. To include more subjects in the study group as well as to extend the laboratory assessment we are in the process of recruiting patients from the Department of Neurology in Zabrze, Medical University of Silesia, Poland. Moreover, the assessment of both nitrogen species and inflammatory parameters in the cerebrospinal fluid may be beneficial for further studies.

6. Conclusions {#sec6}
==============

We observed higher NO~*x*~ activity in MS subjects treated with IFN-*β*1a; IFN-*β*1b as compared to the healthy controls. The results of our study suggest that NO~*x*~ serum level may be a biomarker of MS duration. However, our study did not demonstrate disease activity measured by the EDSS, annual relapse rate, and MRI lesions. Considering the hypothesis that serum NO~*x*~, CRP, and IL-1*β*/IL-1F2 concentrations could reveal potential efficacy of DMT, we reported only significant differences in NO~*x*~ levels depending on various types of DMT. Based on it, we can suggest better reduction of inflammation using the second-line agents of DMT. This issue of MS treatment is intriguing and should be further investigated. Adding antioxidant therapy to the DMTs (with their antioxidative properties) should be well thought out and balanced. Certainly, it requires further investigation in clinical trials.
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###### 

Demographic and clinical characteristics of the study group, depending on different types of disease-modifying therapy.

  Parameters                                                IFN-*β*1a^f^   IFN-*β*1b     GA^g^         NT^h^         FG^i^         CG^j^        *p*
  --------------------------------------------------------- -------------- ------------- ------------- ------------- ------------- ------------ ------
  *N*                                                       22             17            5             7             12            10            
  Age \[years\]                                             41.3 ± 11.7    44.8 ± 10.7   48.6 ± 12.4   33.9 ± 7.7    42.3 ± 13.9   ---          0.27
  Age at the beginning of DMT^a^ \[years\]                  38.8 ± 11.1    42.1 ± 10.8   46.4 ± 12.8   32.3 ± 7.9    40.7 ± 13.5   39.3 ± 3.5   0.38
  Age \[% of females\]                                      68.2           82.4          60.0          85.7          58.3          60.0         0.62
  Time of MS \[months\]                                     57.1 ± 30.8    85.8 ± 72.7   90.2 ± 31.3   81.6 ± 29.3   85.1 ± 33.3   ---          0.14
  Time of DMT \[months\]                                    29.6 ± 13.7    31.4 ± 15.1   26.0 ± 21.8   16.7 ± 6.5    18.7 ± 7.6    ---          0.15
  EDSS^b^ \[score\]                                         2.5 ± 1.07     2.41 ± 0.87   2.60 ± 1.08   2.79 ± 1.11   3.08 ± 1.24   ---          0.83
  ARR^c^ \[*n*\]                                            0.41 ± 0.59    0.35 ± 0.61   0.20 ± 0.45   0.00 ± ND     0.50 ± 0.80   ---          0.58
  T2 MRI^d^ lesions (from the time of diagnosis) \[*n*\]    1.14 ± 0.47    1.18 ± 0.39   1.00 ± ND     1.00 ± ND     1.08 ± 0.29   ---          0.76
  New MRI lesions (within the last year) \[*n*\]            0.09 ± 0.29    0.06 ± 0.24   0.20 ± 0.45   0.00 ± ND     0.33 ± 0.65   ---          0.52
  Gd+^e^ MRI lesions (from the time of diagnosis) \[*n*\]   0.05 ± 0.21    0.12 ± 0.33   20.4 ± 45.1   0.00 ± ND     0.83 ± 1.75   ---          0.20
  New Gd+ MRI lesions (within the last year) \[*n*\]        0.05 ± 0.21    0.06 ± 0.24   0.2 ± 0.45    0.00 ± ND     0.83 ± 1.75   ---          0.35

a: disease-modifying therapy; b: Expanded Disability Status Scale; c: annual relapse rate; d: magnetic resonance imaging; e: Gadovist; f: interferon beta; g: glatiramer acetate; h: natalizumab; i: fingolimod; j: control group.

###### 

Demographic and clinical characteristics of the study group, depending on the line of disease-modifying therapy.

  Parameters                                                LI                   LII           CG^j^         *p*
  --------------------------------------------------------- -------------------- ------------- ------------- -------
  *N*                                                       44                   19            10            ---
  DMT^a^ \[*n*\]                                            IF1a/IF1b^f^/GA^g^   NT^h^/FG^i^   ---           ---
  22/17/5                                                   7/12                                             
  Age \[years\]                                             43.5 ± 11.4          39.2 ± 12.4   ---           0.11
  Age at the beginning of DMT \[years\]                     40.9 ± 11.2          37.6 ± 12.2   39.3 ± 2.47   0.23
  Age \[% of females\]                                      72.7                 68.4          60.0          0.72
  Time of MS \[months\]                                     72.0 ± 52.4          87.8 ± 31.1   ---           0.048
  Time of DMT \[months\]                                    29.9 ± 14.9          17.9 ± 7.1    ---           0.005
  EDSS^b^ \[score\]                                         2.48 ± 0.98          2.97 ± 1.17   ---           0.10
  ARR^c^ \[*n*\]                                            0.36 ± 0.57          0.32 ± 0.67   ---           0.51
  T2 MRI^d^ lesions (from the time of diagnosis) \[*n*\]    1.14 ± 0.41          1.05 ± 0.23   ---           0.45
  New MRI lesions (within the last year) \[*n*\]            0.09 ± 0.29          0.21 ± 0.54   ---           0.42
  Gd+^e^ MRI lesions (from the time of diagnosis) \[*n*\]   2.39 ± 15.2          0.53 ± 1.43   ---           0.60
  New Gd+ MRI lesions (within the last year) \[*n*\]        0.07 ± 0.25          0.53 ± 1.43   ---           0.24

A: disease-modifying therapy; b: Expanded Disability Status Scale; c: annual relapse rate; d: magnetic resonance imaging; e: Gadovist; f: interferon beta; g: glatiramer acetate; h: natalizumab; i: fingolimod; j: control group.

###### 

Laboratory assays in the study group, depending on the type of disease-modifying therapy without the assessment of healthy controls.

  Parameters                    IFN-*β*1a^d^   IFN-*β*1b     GA^e^         NT^f^         FG^g^         *p*
  ----------------------------- -------------- ------------- ------------- ------------- ------------- -------
  *N*                           22             17            5             7             12             
  NO~*x*~ ^a^ \[*µ*M\]          2.25 ± 0.71    1.90 ± 0.69   1.58 ± 0.35   1.65 ± 0.31   1.52 ± 0.31   0.018
  IL-1*β*/IL-1F2^b^ \[pg/mL\]   1.43 ± 0.34    1.56 ± 0.60   1.71 ± 0.41   2.19 ± 1.27   1.51 ± 0.56   0.78
  CRP^c^ \[mg/L\]               2.43 ± 3.14    1.88 ± 1.71   1.72 ± 1.12   0.95 ± 0.79   1.81 ± 2.5    0.79

A: nitric oxide (nitrite and nitrate); b: interleukin; c: C-reactive protein; d: interferon beta; e: glatiramer acetate; f: natalizumab; g: fingolimod.

###### 

Laboratory assays in the study group, depending on the line of disease-modifying therapy.

                                LI            LII           *p*
  ----------------------------- ------------- ------------- -------
  NO~*x*~ ^a^ \[*µ*M\]          2.04 ± 0.70   1.57 ± 0.31   0.003
  IL-1*β*/IL-1F2^b^ \[pg/mL\]   1.51 ± 0.46   1.76 ± 0.92   0.81
  CRP^c^ \[mg/L\]               2.13 ± 2.47   1.49 ± 2.05   0.06

A: nitric oxide (nitrite and nitrate); b: interleukin; c: C-reactive protein.

###### 

Laboratory assays in lower and higher Expanded Disability Status Scale groups.

                                EDSS^a^ 0--3 \[score\]   EDSS \> 3 \[score\]   *p*
  ----------------------------- ------------------------ --------------------- ------
  NO~*x*~ ^b^ \[*µ*M\]          1.97 ± 0.67              1.70 ± 0.53           0.10
  IL-1*β*/IL-1F2^c^ \[pg/mL\]   1.51 ± 0.54              1.78 ± 0.84           0.32
  CRP^d^ \[mg/L\]               2.0 ± 2.45               1.79 ± 2.12           0.76

A: Expanded Disability Status Scale; b: nitric oxide (nitrite and nitrate); c: interleukin; d: C-reactive protein.

###### 

Correlation between nitric oxide (nitrate and nitrite) serum levels and clinical and radiological parameters measured in all multiple sclerosis patients and in groups under first and second line of disease-modifying therapies.

  NO~*x*~ ^a^ \[*µ*M\]                                      MS^f^ patients   LI      LII
  --------------------------------------------------------- ---------------- ------- -------
  *N*                                                       63               44      19
  EDSS^b^ \[points\]                                        −0.19            −0.10   −0.29
  ARR^c^ \[*n*\]                                            −0.007           −0.12   −0.19
  T2 MRI^d^ lesions (from the time of diagnosis) \[*n*\]    −0.05            0.11    −0.28
  New MRI lesions (within the last year) \[*n*\]            −0.05            0.13    −0.41
  Gd+^e^ MRI lesions (from the time of diagnosis) \[*n*\]   −0.14            −0.03   −0.42
  New Gd+ MRI lesions (within the last year) \[*n*\]        −0.22            0.19    −0.42

^*∗*^ *p* \> 0.05 in all analysis.

A: nitric oxide (nitrite and nitrate); b: Expanded Disability Status Scale. C: annual relapse rate; d: magnetic resonance imaging; e: Gadovist; f: multiple sclerosis.

[^1]: Academic Editor: Markus Kipp
